Zhengye Biotechnology (Nasdaq: ZYBT) clears $1.00 bid price hurdle
Rhea-AI Filing Summary
Zhengye Biotechnology Holding Limited reports that Nasdaq has determined it regained compliance with the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). This followed 10 consecutive business days, from July 20 to August 4, 2026, during which its Class A ordinary shares closed at or above $1.00. The company remains listed on The Nasdaq Capital Market under the ticker ZYBT.
Zhengye, through its operating entity in Jilin, China, focuses on research, development, manufacturing, and sales of veterinary vaccines. The operating entity offers 50 vaccines for multiple animal species, sells across 29 provincial regions in China, and exports to Vietnam, Pakistan, and Egypt.
Positive
- Company receives Nasdaq letter confirming compliance with the $1.00 minimum bid price and continues trading on The Nasdaq Capital Market.
Negative
- None.
Key Figures
Minimum bid price requirement: $1.00 per share
Compliance observation period: 10 consecutive business days
Compliance period end date: November 25, 2026
+4 more
7 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) minimum bid price
Compliance observation period
10 consecutive business days
July 20, 2026 to August 4, 2026 with bid at or above $1.00
Compliance period end date
November 25, 2026
End of 180-day period granted to regain minimum bid compliance
Veterinary vaccines portfolio
50 veterinary vaccines
Number of vaccines offered by the operating entity
Geographic coverage in China
29 provincial regions
Chinese regions where products are available
Vaccine production lines
13 vaccine production lines
Within three veterinary vaccine production floors
Years focused on animal health
over 20 years
Operating entity’s history enhancing animal health
Key Terms
Minimum Bid Price Rule, Nasdaq Listing Rule 5550(a)(2), Good Manufacturing Practices for Veterinary Drugs, forward-looking statements, +1 more
5 terms
Minimum Bid Price Rule regulatory
"regained compliance with the Minimum Bid Price Rule."
A minimum bid price rule is a stock market requirement that a listed company's share must trade above a set minimum price over a specified period to remain listed on an exchange. It matters to investors because falling below that threshold can trigger warnings, potential delisting, and reduced liquidity—similar to a student needing a passing grade to stay enrolled—making the shares harder to buy, sell, or value accurately.
Nasdaq Listing Rule 5550(a)(2) regulatory
"compliance with Nasdaq Listing Rule 5550(a)(2)."
Good Manufacturing Practices for Veterinary Drugs technical
"operating in accordance with Good Manufacturing Practices for Veterinary Drugs"
Good manufacturing practices for veterinary drugs are regulatory standards that set how animal medicines must be designed, made, tested and documented to ensure consistent quality, safety and traceability. They cover facilities, equipment, staff training, production procedures and record-keeping—think of them as a strict recipe and kitchen hygiene rules that make every batch reliable. For investors, these rules matter because compliance affects product approvals, market access, liability risk and company reputation.
forward-looking statements regulatory
"This announcement contains statements that may constitute “forward-looking” statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
veterinary vaccines medical
"focus on the research, development, manufacturing, and sales of veterinary vaccines"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Zhengye Biotechnology (ZYBT) announce regarding its Nasdaq listing?
Zhengye Biotechnology announced that Nasdaq confirmed it has regained compliance with the $1.00 minimum bid price rule. After 10 consecutive business days with its share price at or above $1.00, the company continues to be listed on The Nasdaq Capital Market under ticker ZYBT.
How did Zhengye Biotechnology (ZYBT) regain compliance with Nasdaq’s $1.00 bid requirement?
Compliance was regained after the Class A ordinary shares closed at $1.00 or higher for 10 consecutive business days from July 20 to August 4, 2026. Nasdaq then issued a compliance letter on August 5, 2026 confirming that the minimum bid price rule was satisfied.
What was the original Nasdaq deficiency notice timeline for ZYBT?
On May 29, 2026 Zhengye Biotechnology received a Nasdaq notice that its shares traded below $1.00 for 30 consecutive business days. The company was granted a 180-day compliance period, until November 25, 2026, to restore compliance with the minimum bid price requirement.
What business does Zhengye Biotechnology (ZYBT) operate in?
Zhengye Biotechnology operates through an entity in Jilin, China focused on veterinary vaccines. It engages in research, development, manufacturing, and sales of 50 vaccines for swine, cattle, goats, sheep, poultry, and dogs, emphasizing livestock vaccines in China and select overseas markets.
Where are Zhengye Biotechnology’s (ZYBT) veterinary vaccines sold and produced?
The operating entity’s products are sold in 29 provincial regions across China and exported to Vietnam, Pakistan, and Egypt. Production occurs on three veterinary vaccine production floors with 13 production lines, plus a quality examination center and animal facility operating under Chinese GMP standards.